KR101987512B1 - 자기 면역 질환 치료용 조성물 및 방법 - Google Patents

자기 면역 질환 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR101987512B1
KR101987512B1 KR1020147010372A KR20147010372A KR101987512B1 KR 101987512 B1 KR101987512 B1 KR 101987512B1 KR 1020147010372 A KR1020147010372 A KR 1020147010372A KR 20147010372 A KR20147010372 A KR 20147010372A KR 101987512 B1 KR101987512 B1 KR 101987512B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutical composition
composition according
mice
eae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147010372A
Other languages
English (en)
Korean (ko)
Other versions
KR20140082982A (ko
Inventor
레자 파티
패트릭 라프린 매클레인
해리 제퍼슨 레이턴
Original Assignee
레드힐 바이오파마 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47914967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101987512(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레드힐 바이오파마 엘티디 filed Critical 레드힐 바이오파마 엘티디
Publication of KR20140082982A publication Critical patent/KR20140082982A/ko
Application granted granted Critical
Publication of KR101987512B1 publication Critical patent/KR101987512B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147010372A 2011-09-20 2012-09-19 자기 면역 질환 치료용 조성물 및 방법 Expired - Fee Related KR101987512B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161536824P 2011-09-20 2011-09-20
US61/536,824 2011-09-20
US201161537229P 2011-09-21 2011-09-21
US61/537,229 2011-09-21
PCT/IB2012/002252 WO2013041963A2 (en) 2011-09-20 2012-09-19 A composition and method for treating an autoimmune disease

Publications (2)

Publication Number Publication Date
KR20140082982A KR20140082982A (ko) 2014-07-03
KR101987512B1 true KR101987512B1 (ko) 2019-06-10

Family

ID=47914967

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010372A Expired - Fee Related KR101987512B1 (ko) 2011-09-20 2012-09-19 자기 면역 질환 치료용 조성물 및 방법

Country Status (22)

Country Link
US (1) US9901638B2 (cg-RX-API-DMAC7.html)
EP (1) EP2758061B1 (cg-RX-API-DMAC7.html)
JP (1) JP6035340B2 (cg-RX-API-DMAC7.html)
KR (1) KR101987512B1 (cg-RX-API-DMAC7.html)
CN (1) CN103813797B (cg-RX-API-DMAC7.html)
AU (1) AU2012311235B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014006473A2 (cg-RX-API-DMAC7.html)
CA (1) CA2849255C (cg-RX-API-DMAC7.html)
CL (1) CL2014000671A1 (cg-RX-API-DMAC7.html)
DK (1) DK2758061T3 (cg-RX-API-DMAC7.html)
ES (1) ES2614923T3 (cg-RX-API-DMAC7.html)
HU (1) HUE032959T2 (cg-RX-API-DMAC7.html)
IL (1) IL231489A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02908A (cg-RX-API-DMAC7.html)
MX (1) MX347660B (cg-RX-API-DMAC7.html)
PL (1) PL2758061T3 (cg-RX-API-DMAC7.html)
PT (1) PT2758061T (cg-RX-API-DMAC7.html)
RU (1) RU2621129C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201400386RA (cg-RX-API-DMAC7.html)
TW (1) TWI573590B (cg-RX-API-DMAC7.html)
WO (1) WO2013041963A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401954B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2991649B1 (en) * 2013-04-30 2020-06-03 Thomas Julius Borody Compositions for treating obsessive-compulsive disorder
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication
CA2997671A1 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
BR112022026615A2 (pt) * 2020-06-30 2023-01-24 Redhill Biopharma Ltd Produtos combinados em dose tripla fixa de antibióticos, regime de dosagem, métodos e kits para tratamento de infecções por micobactérias pulmonares não tuberculosas
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬
CN116649295A (zh) * 2023-03-20 2023-08-29 广西医科大学第一附属医院 GluN1359-378多肽主动免疫PTZ诱发癫痫及认知障碍的动物模型、建立方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080275063A1 (en) 2007-04-24 2008-11-06 Heike Schauerte Inhibitors of protein kinases
US7488580B1 (en) 2005-03-10 2009-02-10 University Of Central Florida Research Foundation, Inc. Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood
US20110059136A1 (en) 2008-02-08 2011-03-10 Thomas Julius Borody Methods and Compositions for Treating Inflammatory Bowel Disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2285923C (en) 1997-04-01 2013-03-12 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US20090054380A1 (en) * 2005-12-20 2009-02-26 Greenstein Robert J Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
EP2200613B1 (en) * 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US20120237472A1 (en) * 2009-07-24 2012-09-20 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488580B1 (en) 2005-03-10 2009-02-10 University Of Central Florida Research Foundation, Inc. Protocol for detection of Mycobacterium avium subspecies paratuberculosis in blood
US20080275063A1 (en) 2007-04-24 2008-11-06 Heike Schauerte Inhibitors of protein kinases
US20110059136A1 (en) 2008-02-08 2011-03-10 Thomas Julius Borody Methods and Compositions for Treating Inflammatory Bowel Disease

Also Published As

Publication number Publication date
US20140228307A1 (en) 2014-08-14
RU2621129C2 (ru) 2017-05-31
HUE032959T2 (hu) 2017-11-28
CN103813797A (zh) 2014-05-21
EP2758061B1 (en) 2016-11-16
IL231489A (en) 2017-01-31
SG11201400386RA (en) 2014-09-26
CN103813797B (zh) 2017-07-11
TWI573590B (zh) 2017-03-11
CA2849255C (en) 2019-06-04
JP6035340B2 (ja) 2016-11-30
IN2014CN02908A (cg-RX-API-DMAC7.html) 2015-07-03
JP2014526548A (ja) 2014-10-06
ZA201401954B (en) 2016-06-29
IL231489A0 (en) 2014-04-30
CA2849255A1 (en) 2013-03-28
MX2014003430A (es) 2014-07-28
RU2014115807A (ru) 2015-10-27
TW201320999A (zh) 2013-06-01
AU2012311235B2 (en) 2017-02-02
DK2758061T3 (en) 2017-02-20
BR112014006473A2 (pt) 2017-03-28
AU2012311235A1 (en) 2014-03-20
US9901638B2 (en) 2018-02-27
WO2013041963A2 (en) 2013-03-28
KR20140082982A (ko) 2014-07-03
ES2614923T3 (es) 2017-06-02
PT2758061T (pt) 2017-02-14
CL2014000671A1 (es) 2014-10-03
EP2758061A4 (en) 2015-02-25
EP2758061A2 (en) 2014-07-30
WO2013041963A3 (en) 2013-06-06
MX347660B (es) 2017-05-08
PL2758061T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
KR20140082982A (ko) 자기 면역 질환 치료용 조성물 및 방법
KR101740893B1 (ko) Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
Serpe et al. Kinetics of facial motoneuron loss following facial nerve transection in severe combined immunodeficient mice
DE69837324T2 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
KR20120104422A (ko) 중추신경계 (cns) 자가면역 탈수초 질환의 치료 또는 예방을 위한 디아족사이드
US5795563A (en) Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
CN115154447B (zh) 一种2,6-二(2-(三氟甲基)苯亚甲基)环己酮在炎症性肠病药物制备中的应用
CN107970238A (zh) 苦参碱在制备抑制神经炎症药物中的应用
Chaiworaporn et al. Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment
CN108685903B (zh) 鼠尾草酚在制备防治实验性自身免疫性脑脊髓炎药物的应用
CN112402420A (zh) 钩吻素子在制备用于治疗炎症性肠病的药物中的用途
US8349314B2 (en) Method of treating and/or preventing type II diabetes using Actinomycetales
US20090280146A1 (en) Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
CN113181182A (zh) 伪石蒜碱在制备预防和/或治疗多发性硬化症的药物中的用途
EP3621628B1 (en) Method for treating multiple sclerosis using arsenic trioxide
KR101929682B1 (ko) 올러유러핀을 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물
JP7337389B2 (ja) ヒアルロン酸を有効成分として含むアレルゲン作用増強剤
KR100742189B1 (ko) 양제근 추출물을 함유한 아토피 피부염 치료용 조성물
KR100329835B1 (ko) 베체트병 치료에 사용되는 수산화 알루미늄 애쥬번트에흡착된 오발부민을 포함하는 티에이치2 애쥬번트
CN119656193A (zh) 外囊泡治疗神经元损伤的应用
KR20260021014A (ko) 근위축성 측삭 경화증(als)의 치료
Jakobsen et al. Inhibition of LPS and Plasmodium falciparum induced cytokine secretion by pentoxifylline and two analogues
CN116889572A (zh) 环烯醚萜类化合物在制备预防和/或治疗多发性硬化症的药物中的用途
CN118078816A (zh) 谷美替尼在制备促进髓鞘形成和再生的药物中的应用
WO2018082034A1 (en) Uses of triterpenoid mixture for treating multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220407

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230604

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230604